High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration

23 October 2018

Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.

The OpACIN-Neo study, led by a team out of the Netherlands with a large number of patients recruited from Melanoma Institute Australia, showed a modified combination of the immunotherapies ipilimumab and nivolumab given prior to surgery produced a response in over 70% of patients. Importantly, there were drastically reduced side effects for patients and remarkably, none of these patients have relapsed to date.

Stage III patients are those whose melanoma has spread to their lymph nodes. Standard therapy for these patients is to undergo surgery to remove their melanoma, however those who undergo surgery alone have a significant risk (40-70%) of their disease recurring and progressing to Stage IV. Research in Stage IV melanoma patients demonstrates that combining ipilimumab and nivolumab is more effective than nivolumab alone, however this combination of drugs often causes extreme side effects for patients with many unable to continue treatment. Extrapolating from this data, the OpACIN-Neo study aimed to modify the dose of combined ipilimumab and nivolumab to reduce the incidence of toxicity while extending the efficacy seen in Stage IV patients to those with high-risk Stage III disease.

Previous research has shown that giving immunotherapy prior to surgery shrank the number of melanoma cells and increased long-term relapse-free survival. Neoadjuvant (pre-surgery) ipilimumab and nivolumab was also found to induce a stronger immune response, leading researchers to believe that when the immunotherapy is able to see the melanoma cells, they are able to assist the immune system to mount a more effective response.

In the OpACIN-Neo trial, researchers modified the standard dosing schedule by decreasing the dose of ipilimumab and increasing the dose of nivolumab and gave these prior to surgery. They found that after six weeks of therapy, the toxicity of the combination therapy was drastically reduced (only 20% of patients suffered a severe toxicity compared with those who received the standard dosing in that 6 weeks) while the efficacy was largely unchanged with a pathologic response seen in 77% of patients.

"These results are promising in that they provide an insight into the effects of altering the dosage and timing of giving combination immunotherapy to Stage III melanoma patients," said Co-Medical Director of Melanoma Institute Australia, Professor Georgina Long. "To have such a high level of response, coupled with greatly reduced toxicity for patients, means we are heading in the right direction with this vital area of immunotherapy research. The high rate of pathological response is exciting, as we know from a pilot study that those patients who had a pathological response haven’t had disease recurrence."

Stage III melanoma patients with bulky lymph node disease have the worst prognosis of Stage III patients, with 70-80% of them expected to recur within the first two years. After three years of follow-up in this pilot study, every patient who presented with a pathological response is yet to recur.

Promising results from a host of clinical trials investigating the use of neoadjuvant therapies in metastatic melanoma are being analysed by the International Neoadjuvant Melanoma Consortium, which also met at ESMO. This international group of researchers and clinicians aims to increase collaboration and standardise efforts in neoadjuvant treatment for melanoma. "This is one of the most exciting things happening in drug therapy in melanoma and has the capacity to ultimately change clinical practice around the world," Professor Long added.

Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
13 Feb 2018

Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide

The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.

Prestigious award in pathology for Professor Scolyer
09 Feb 2018

Prestigious award in pathology for Professor Scolyer

Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.

A Day in the Life Of... Serigne Lo
09 Feb 2018

A Day in the Life Of... Serigne Lo

A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia

Jay inspires others to help end melanoma and so can you
07 Feb 2018

Jay inspires others to help end melanoma and so can you

Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.

A dilemma no mother-to-be should face
31 Jan 2018

A dilemma no mother-to-be should face

Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment

Join little Madi and Bettina in the fight against melanoma
25 Jan 2018

Join little Madi and Bettina in the fight against melanoma

Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.

Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
19 Jan 2018

Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma

Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!

Sun Protection: Facts and Controversies
18 Jan 2018

Sun Protection: Facts and Controversies

MIA's dermatologist shares her knowledge with GPs on debunking myths and controversies on sunscreen.

Shannan Ponton joins our March for a cure
17 Jan 2018

Shannan Ponton joins our March for a cure

Shannan Ponton thought he was invincible – he wasn’t. But his melanoma battle ended up saving more than his own life. 

Surprising finding in rare form of melanoma get patients closer to personalised medicine
11 Jan 2018

Surprising finding in rare form of melanoma get patients closer to personalised medicine

Researchers have demonstrated that immunotherapy is highly effective in treating a rare form of melanoma – a result that is surprising due to the nature of the tumour.  

Using new technology to prevent melanoma
14 Dec 2017

Using new technology to prevent melanoma

Innovation is helping to prevent melanoma developing in the first place.

Research review of 2017
12 Dec 2017

Research review of 2017

Research from MIA is changing the way melanoma is managed worldwide and improving patient survival. Here are a few of our key highlights from this year.

Translational research funding boost
24 Nov 2017

Translational research funding boost

A prestigious Fellowship has been awarded to fund research that will change the way melanoma treatment is assessed in the future.

New research to guide clinicians to more accurately stage and manage melanoma patients
16 Nov 2017

New research to guide clinicians to more accurately stage and manage melanoma patients

New research from MIA has been published that forms the basis of the updated international guidelines for staging melanoma.

Founding father recognised for outstanding cancer care
15 Nov 2017

Founding father recognised for outstanding cancer care

Professor William McCarthy AM has been awarded the Tom Reeve Award for Outstanding Contributions to Cancer Care.

Melanoma researchers shine at the State's premier cancer awards ceremony
03 Nov 2017

Melanoma researchers shine at the State's premier cancer awards ceremony

Leading researchers from MIA have been acknowledged with three prestigious awards for excellence in melanoma research.

Enhancing melanoma treatment response through gut bacteria
03 Nov 2017

Enhancing melanoma treatment response through gut bacteria

New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.

Melanoma March is just around the corner!
01 Nov 2017

Melanoma March is just around the corner!

2018 will be bigger than ever, and a little bit different.

Comparing melanoma risk in similar populations across different latitudes
20 Oct 2017

Comparing melanoma risk in similar populations across different latitudes

MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.

Congratulations to our Conjoint Medical Directors
19 Oct 2017

Congratulations to our Conjoint Medical Directors

Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.